Apellis Pharmaceuticals Q4 EPS $(0.73) Misses $(0.69) Estimate, Sales $146.38M Beat $143.59M Estimate
Portfolio Pulse from Benzinga Newsdesk
Apellis Pharmaceuticals (NASDAQ:APLS) reported Q4 earnings with a per-share loss of $(0.73), missing the $(0.69) estimate, but saw sales of $146.38M, exceeding the $143.59M estimate. This represents a significant improvement over the previous year, with a 51.33% decrease in losses and a 545.89% increase in sales.
February 27, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Apellis Pharmaceuticals reported a Q4 EPS loss of $(0.73), missing estimates, but exceeded sales expectations with $146.38M. Year-over-year, the company significantly reduced losses and increased sales.
While Apellis Pharmaceuticals missed EPS estimates, the significant sales beat and dramatic year-over-year improvements in both losses and sales could balance investor sentiment. The mixed results present a neutral short-term impact on the stock price, as the sales beat may offset concerns over the EPS miss.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100